证券代码：600196 股票简称：复星医药 编号：临 2025-128 上海复星医药（集团）股份有限公司 关于股东部分股份质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） ● 截 至 2025 年 8 月 14 日 收 市 ， 控 股 股 东 复 星 高 科 技 持 有 本 公 司 961,424,455 股股份（其中：A 股 889,890,955 股、H 股 71,533,500 股），约占 截至当日收市本公司股份总数的 36.00%。本次质押及解除质押后，复星高科技 质押本公司股份数量余额为 612,675,000 股（均为 A 股），约占截至当日收市本 公司股份总数的 22.94%。 ● 截至 2025 年 8 月 14 日收市，控股股东复星高科技及其一致行动人（即 复星高科技董监高、复星国际有限公司及其董高<包括本公司实际控制人>，下同） 合计持有本公司967,812,180股股份（其中：A股890,278,680股、H股77,533,500 股），约占截至当日收市本公 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-129 上海复星医药（集团）股份有限公司 关于参与认购之私募股权投资基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、标的基金概况 2022 年 4 月，包括本公司在内的首轮募集合伙人签订《上海景旭榕熙合伙协议》， 本公司出资人民币 6,000 万元参与标的基金首轮募集，该基金首轮募集资金总额为 人民币 15,000 万元。2022 年 11 月，标的基金于中基协完成私募投资基金备案。以 上详情请见本公司 2022 年 4 月 12 日、2022 年 11 月 26 日于《中国证券报》《上海 证券报》《证券时报》和上海证券交易所网站(https://www.sse.com.cn)发布的相 关公告。 自2022年11月上海景旭榕煦备案完成至本公告日期（即2025年8月15日暨本次减 资前，下同）期间，该基金完成第二轮募集，总募集规模由人民币15,000万元增至 20,000万元，本公司未参与第二轮募集。 二、进展情况 因资金安排及出资要求等方面原因 ...

Core Viewpoint - Fosun Pharma's stock has seen a significant increase, rising over 6% and currently trading at 21.06 HKD, with a transaction volume of 299 million HKD, following the announcement of a licensing agreement with Expedition for the global development of the drug XH-S004 outside of China and Hong Kong [1] Group 1: Licensing Agreement - Fosun Pharma's subsidiary has signed a licensing agreement with Expedition, granting them rights to develop, produce, and commercialize the investigational product XH-S004 globally, excluding China and Hong Kong [1] - Expedition will pay up to 120 million USD in non-refundable upfront payments and milestone payments based on development and regulatory achievements, as well as up to 525 million USD in sales milestone payments based on annual net sales in the licensed regions [1] Group 2: Market Potential and Clinical Trials - The DPP-1 inhibitor drug market is identified as having significant potential, with Fosun Pharma's XH-S004 currently in Phase II clinical trials for non-cystic fibrosis bronchiectasis and in Phase Ib for chronic obstructive pulmonary disease in China [1] - The company has invested a total of 72 million RMB in research and development for this innovative product, and the licensing agreement is expected to enhance the valuation of its pipeline of innovative drugs [1]

Core Viewpoint - Fosun Pharma's stock has seen a significant increase, rising over 6% and currently trading at 21.06 HKD, with a transaction volume of 299 million HKD, following the announcement of a licensing agreement with Expedition for the development and commercialization of the drug XH-S004 outside of China and Hong Kong [1] Group 1 - Fosun Pharma's subsidiary has signed a licensing agreement with Expedition, granting global rights for the development, production, and commercialization of the investigational product XH-S004, excluding China and Hong Kong [1] - Expedition will pay up to 120 million USD in non-refundable upfront payments and milestone payments based on development and regulatory achievements, as well as up to 525 million USD in sales milestone payments based on annual net sales in the licensed regions [1] - The DPP-1 inhibitor drug market is identified as having significant potential, with Fosun Pharma's XH-S004 currently in Phase II clinical trials for non-cystic fibrosis bronchiectasis and Phase I clinical trials for chronic obstructive pulmonary disease in China [1] Group 2 - Fosun Pharma has invested a total of 72 million RMB in research and development for the XH-S004 drug [1] - The licensing agreement is seen as a recognition of the company's innovative drug pipeline by foreign investment and research teams, which may lead to a reassessment of the company's innovative drug development pipeline [1]

Group 1 - Shanghai Fosun Pharmaceutical Group Co., Ltd. successfully issued the first private pharmaceutical industry medium to long-term technology innovation bond in China, with a scale of 1 billion RMB and a maturity of 2 years at a coupon rate of 2.70% [2] - The bond received enthusiastic subscriptions from various financial institutions, including bank wealth management, insurance, foreign banks, public funds, and securities firms [2] - The successful issuance of the technology innovation bond further consolidates Fosun Pharma's leading position among domestic innovative pharmaceutical companies and supports the company's high-quality development [3] Group 2 - Fosun Pharma has been driven by innovation for over 30 years, having approved 12 self-developed and licensed innovative drugs and biosimilars since 2019 [3] - The company has secured commercial rights for 8 innovative drugs in China, covering key treatment areas such as solid tumors, hematological tumors, and immune inflammation [3] - Fosun Pharma aims to deepen its innovation transformation and provide better and more accessible products and services for patients and clients, while creating sustainable value returns for shareholders [3]

Summary of Key Points from the Conference Call on China Healthcare Industry Overview - The conference focused on the **China Healthcare** sector, particularly the pharmaceutical and biotech industries, highlighting the attractive investment landscape in the Asia Pacific region [2][5][6]. Core Insights and Arguments - **Growth Projections**: The global pharmaceutical market is expected to grow at a **CAGR of 5.7%** from 2023 to 2028, while the Chinese pharmaceutical market is projected to grow at a **CAGR of 7.7%** during the same period [9][12]. - **Market Dynamics**: The Chinese pharmaceutical market is characterized by a significant reliance on imported products, particularly in the albumin segment, where **60-70%** of the market is composed of imports [34]. - **Out-licensing Trends**: There has been a notable increase in out-licensing activities, with over **$50 billion** in deals recorded in 2024, driven by narrowing innovation gaps and emerging complex modalities [41][42]. - **Regulatory Environment**: The plasma industry in China faces high entry barriers, with only **<30 plasma fractionators** currently operating, leading to a market consolidation trend [33][34]. Important Developments - **Upcoming Events**: Key sector events include the **CSCO 2025** and **WCLC 2025** conferences, which are expected to influence stock performance in the pharmaceutical and biotech sectors [6][8]. - **Pipeline Assets**: Several companies, including Hengrui and CSPC, have significant pipeline assets with upcoming drug approvals and trial progress expected in **2H25** [32][27]. Potential Risks and Challenges - **Supply Constraints**: The Chinese plasma market is underdeveloped compared to global standards, with a limited variety of plasma derivatives available [34]. - **Market Competition**: The top five plasma companies dominate approximately **60%** of the market, indicating a highly consolidated competitive landscape [33]. Additional Insights - **Investment Sentiment**: The overall sentiment towards the China healthcare sector remains positive, with analysts highlighting the potential for significant returns driven by innovation and market expansion [2][41]. - **Technological Advancements**: The introduction of recombinant human albumin (rHSA) is expected to disrupt the albumin market, potentially capturing **~10%** of the total market share [35]. This summary encapsulates the key points discussed during the conference call, providing a comprehensive overview of the current state and future outlook of the China healthcare sector.

中证报中证网讯(记者李梦扬)8月14日，记者获悉，复星医药（600196）近日成功发行全国首单民营医 药行业中长期科技创新债券，由招商银行担任牵头主承销商兼簿记管理人，北京银行、浦发银行担任联 席承销商，规模10亿元，期限2年，票面利率2.70%。 据了解，创立30多年来，复星医药始终以创新为核心发展驱动力。在创新药领域，自2019年以来，复星 医药已累计获批12款自主研发、许可引进的创新药和生物类似药，同时成功获得8款创新药物的中国境 内商业化权益，涵盖实体瘤、血液瘤、免疫炎症等核心治疗领域。2025年至今，复星医药已有4款产品5 项适应症在中国及欧盟等多地获批。复星医药表示，未来公司将继续深化创新转型，致力于为患者和客 户提供更优质、更可及的产品和服务，为股东创造可持续的价值回报。 2025年5月7日，中国人民银行、中国证监会联合发布关于支持发行科技创新债券有关事宜的公告；同 日，中国银行间市场交易商协会发布了《关于推出科技创新债券构建债市"科技板"的通知》，提出多项 科技创新债券配套支持机制，引导债券资金更加高效、便捷、低成本投向科技创新领域，提升债券市场 服务科技创新能力。 在此背景下，复星医药表示， ...

Group 1 - Recently, Fosun Pharma successfully issued the first long-term technology innovation bond in the private pharmaceutical sector in China, with a scale of 1 billion RMB, a term of 2 years, and a coupon rate of 2.70% [1] - The bond received enthusiastic subscriptions from various financial institutions, including bank wealth management, insurance, foreign banks, public funds, and securities firms, indicating strong market support [1][2] - The funds raised will provide strong financial support for Fosun Pharma's layout in key technology innovation areas, accelerating the transformation and implementation of innovative results [1] Group 2 - The issuance of this technology innovation bond aligns with the central government's policies to support the healthy and high-quality development of the private economy, as emphasized in recent meetings and action plans [1][2] - Fosun Pharma has been focusing on innovation as its core development driver for over 30 years, having received approvals for 12 self-developed and licensed innovative drugs since 2019, covering critical treatment areas [3] - The company aims to deepen its innovation transformation and provide high-quality, accessible products and services to patients and customers, while creating sustainable value returns for shareholders [3]

Core Viewpoint - The valuation logic of Fosun Pharma is undergoing a silent reconstruction following a significant licensing deal for its innovative drug XH-S004, which has led to a notable increase in its stock price and market recognition [1][3]. Group 1: Licensing Deal and Market Reaction - Fosun Pharma announced a global licensing agreement for its oral DPP-1 inhibitor XH-S004 with Expedition Therapeutics, with a potential total transaction value of $645 million (approximately 4.6 billion RMB) [1]. - Following the announcement, Fosun Pharma's H-shares surged by 9.4% and A-shares rose by 5.6%, indicating strong market approval of the deal [1]. - XH-S004 is currently in Phase II clinical trials for non-cystic fibrosis bronchiectasis and Phase Ib trials for chronic obstructive pulmonary disease (COPD) in China [1]. Group 2: Strategic Partnerships and Market Position - Expedition Therapeutics focuses on innovative therapies for autoimmune diseases and has a management team with extensive experience in drug development and commercialization [2]. - The collaboration aims to expand the global reach of XH-S004 for treating non-cystic fibrosis bronchiectasis and COPD patients [2]. - The DPP-1 inhibitor market is becoming increasingly competitive, with major pharmaceutical companies like Merck and GSK investing in this area, highlighting the growing demand for treatments for chronic lung diseases [2]. Group 3: Financial and Market Performance - Fosun Pharma's strategic transformation is reflected in its recent issuance of 1 billion RMB in technology innovation bonds, which received a favorable interest rate of 2.70%, showcasing market confidence in its innovative capabilities [3]. - The stock price of its subsidiary, Fosun Pharma's subsidiary Hanhai, has increased by nearly 235% year-to-date, with a total market capitalization of 43.1 billion HKD [3]. - Hanhai's stock performance is closely linked to its innovative product pipeline, particularly in the lung cancer treatment space, with multiple products gaining recognition at major conferences [3][4]. Group 4: Valuation and Investment Strategy - The innovative pipeline, including HLX43, is expected to drive further stock price increases for Hanhai, although it is not yet included in the Hong Kong Stock Connect, limiting direct investment opportunities for some domestic investors [5]. - Investors are advised to consider holding Fosun Pharma to indirectly benefit from Hanhai's innovation while enjoying the stability and risk mitigation from the parent company's diversified business ecosystem [5]. - As of the latest closing on August 14, Fosun Pharma's H-shares were priced at 19.96 HKD, representing a 34% discount compared to its A-share price of 27.97 RMB, indicating a significant valuation gap [5].

Core Viewpoint - The valuation logic of Fosun Pharma is undergoing a silent reconstruction following a $645 million licensing deal for its innovative drug XH-S004, which has seen a 235% year-to-date increase in its subsidiary, Fosun Hani. [1][3] Group 1: Licensing Deal and Market Reaction - Fosun Pharma announced a global licensing agreement (excluding China and Hong Kong) for its small molecule oral DPP-1 inhibitor XH-S004 with Expedition Therapeutics, with a potential total deal value of $645 million (approximately 4.6 billion RMB) [1] - Following the announcement, Fosun Pharma's H-shares surged by 9.4% and A-shares rose by 5.6%, indicating strong market approval for the deal [1] - XH-S004 is currently in Phase II clinical trials for non-cystic fibrosis bronchiectasis and Phase Ib trials for chronic obstructive pulmonary disease (COPD) in China [1] Group 2: Strategic Partnership and Market Position - Expedition Therapeutics focuses on innovative therapies for autoimmune diseases and has a management team with extensive experience in drug development and commercialization [2] - The partnership aims to expand the global reach of XH-S004 for patients with non-cystic fibrosis bronchiectasis and COPD [2] - The global demand for DPP-1 inhibitors is increasing due to the growing population of chronic lung disease patients, with major pharmaceutical companies like Merck and GSK intensifying their focus on this segment [2] Group 3: Innovation and Financial Performance - Fosun Pharma's licensing deal reflects the market's recognition of its pipeline value and the success of its strategic transformation [3] - The company recently issued 1 billion RMB in technology innovation bonds, marking the first mid-to-long-term technology innovation bond in China's private pharmaceutical sector, showcasing strong capital market support for its innovation efforts [3] - Fosun Hani's stock has increased by nearly 235% year-to-date, with a market capitalization of 43.1 billion HKD, driven by multiple innovative products [3] Group 4: Product Development and Clinical Advancements - HLX43, a PD-L1 ADC, is the first of its kind to enter Phase II clinical trials globally, demonstrating high response rates in specific patient groups [4] - The dual mechanism of HLX43, combining immune checkpoint blockade and cytotoxic payload, addresses treatment challenges for PD-1/L1 resistant patients, making it a notable innovation in lung cancer therapy [4] Group 5: Investment Strategy and Valuation - With the progress of HLX43 and other innovative pipelines, Fosun Hani's stock price is expected to continue rising, although it is not yet included in the Hong Kong Stock Connect, limiting direct investment opportunities for some domestic investors [5] - Investors can benefit from holding Fosun Pharma to indirectly gain from Fosun Hani's innovation value while enjoying the stability and risk mitigation from the parent company's diversified business ecosystem [5] - As of the latest closing on August 14, Fosun Pharma's H-shares were priced at 19.96 HKD, representing a 34% discount compared to its A-share price of 27.97 RMB, highlighting a significant valuation gap [5]